Theraclion Secures €4.8M Funding to Advance Non-Invasive Ultrasound Therapy for Varicose Veins

VCBeat (WeChat ID: vcbeat) has learned that medical device company Theraclion recently secured €4.8 million in financing. The funds will be used to develop a non-invasive ultrasound therapy for varicose veins. This round of financing was provided by Unigestion, a Swiss asset management firm. Following the completion of the financing, Bödtker, Chairman of Unigestion, joined Theraclion’s Board of Directors.

Theraclion, founded in 2004, is a medical device company based in Paris, France, dedicated to developing non-invasive ultrasound therapies for patients with benign tumors. It is the only company worldwide offering non-invasive treatment solutions for patients with breast fibroadenomas and benign thyroid conditions. Theraclion has developed a device called Echopulse, which combines high-intensity focused ultrasound (HIFU) therapy with real-time ultrasound monitoring, enabling non-invasive and outpatient treatment for patients with benign tumors. Currently, Echopulse has obtained CE certification in the European Union.

In 2017, due to sluggish sales of Echopulse in the markets for breast fibroadenomas and benign thyroid diseases, Theraclion targeted a new market: varicose veins. Theraclion found that Echopulse demonstrated favorable efficacy in treating varicose veins. Varicose veins are the most common disorder of the venous system, resulting from congenital weakness of the vascular wall membranes or prolonged maintenance of the same posture, which leads to blood pooling in the lower extremities. Over time, this damages the venous valves and causes elevated venous pressure. Common treatment methods include sclerotherapy injections and surgical stripping.

Theraclion offers the first non-invasive treatment solution for patients with varicose veins. Patients do not need to undergo surgery, the treatment process leaves no scars, and they can be discharged quickly, effectively reducing treatment costs. Meanwhile, David Caumartin, General Manager of Theraclion, stated, “We are planning to change our business model. In the future, we will no longer sell Echopulse; instead of requiring a purchase, patients and doctors will be able to use the device on demand, and we will charge only usage and treatment fees.”

Unigestion, founded in 1971 and headquartered in Geneva, Switzerland, is an asset management firm dedicated to providing tailored investment solutions for high-potential companies. The firm manages approximately $23.2 billion in assets.

(Compiled by Jiao Yanli)